ISPC

+ Watchlist + Portfolio

iSpecimen Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.14
52-Week Range: $1.04 – $46.40
Market Cap: $2.72M
P/E (TTM): —
EPS (TTM): -52.98
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.95
PEG Ratio: —
Return on Equity: -968.47%
Return on Assets: -87.69%
Gross Margin: -108.26%
Operating Margin: -897.05%
Profit Margin: 0.00%
Current Ratio: 0.82
Debt/Equity: 0.14
Total Debt: $240.90K
Free Cash Flow: $-5.58M
Revenue Growth: -78.70%
Earnings Growth: —
Enterprise Value: $-1.45M

ISPC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$10.40M	$9.93M	$9.29M	$1.93M
Cost of Revenue	$4.76M	$4.82M	$5.30M	$1.90M
Gross Profit	$5.65M	$5.11M	$3.99M	$24.11K
Research & Development	$2.66M	$3.57M	$3.53M	$2.16M
Selling, General & Admin	$12.37M	$11.68M	$12.65M	$6.60M
Operating Expenses	$15.83M	$16.28M	$16.72M	$9.00M
Operating Income	-$10.19M	-$11.17M	-$12.73M	-$8.98M
EBITDA	-$8.80M	-$8.75M	-$9.98M	-$8.75M
Pretax Income	-$10.25M	-$11.10M	-$12.50M	-$10.49M
Net Income	-$10.25M	-$11.10M	-$12.50M	-$10.49M
Diluted EPS	-928.00	-982.00	-703.20	-91.20
Diluted Shares	11055	11301	17771	115061

ISPC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.31M	$2.34M	$1.88M	$6.88M
Receivables	$4.07M	$2.94M	$1.44M	$48.30K
Inventory	—	—	$45.11K	$0.00
Current Assets	$19.68M	$8.24M	$3.59M	$6.95M
Total Assets	$24.62M	$15.82M	$9.35M	$9.53M
Current Liabilities	$4.28M	$6.05M	$5.77M	$6.23M
Total Debt	$185.85K	$196.24K	$312.17K	$268.80K
Total Liabilities	$4.31M	$6.08M	$6.04M	$6.44M
Retained Earnings	-$48.27M	-$59.36M	-$71.86M	-$82.35M
Shareholders' Equity	$20.31M	$9.74M	$3.31M	$3.09M
Working Capital	$15.39M	$2.19M	-$2.18M	$723.28K

ISPC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.82M	-$5.81M	-$8.26M	-$4.24M
Capital Expenditure	-$3.19M	-$4.74M	-$709.83K	-$1.00M
Free Cash Flow	-$9.01M	-$10.55M	-$8.97M	-$5.24M
Depreciation & Amortisation	$1.21M	$2.12M	$2.29M	$1.73M
Stock-Based Compensation	$678.61K	$459.67K	$249.68K	$21.27K
Investing Cash Flow	-$3.19M	-$7.23M	$1.98M	-$1.00M
Financing Cash Flow	-$3.42M	$70.89K	$5.82M	$10.24M
Net Change in Cash	-$12.43M	-$12.97M	-$465.26K	$5.00M

ISPC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.06M	$713.13K	$106.59K	$51.76K	$156.01K	$151.94K
Cost of Revenue	$657.28K	$444.18K	$204.59K	$598.84K	$84.41K	$83.29K
Gross Profit	$400.23K	$268.96K	-$98.00K	-$547.08K	$71.60K	$68.65K
Research & Development	$545.37K	$536.31K	$551.10K	$527.03K	$247.55K	$290.23K
Selling, General & Admin	$1.11M	$1.21M	$2.00M	$2.28M	$2.22M	$986.97K
Operating Expenses	$2.04M	$2.09M	$2.73M	$2.14M	$2.61M	$1.43M
Operating Income	-$1.64M	-$1.82M	-$2.83M	-$2.69M	-$2.54M	-$1.36M
EBITDA	-$1.21M	-$614.51K	-$2.32M	-$4.59M	-$2.14M	-$1.16M
Pretax Income	-$1.66M	-$1.05M	-$2.78M	-$5.00M	-$2.28M	-$1.36M
Net Income	-$1.66M	-$1.05M	-$2.78M	-$5.00M	-$2.28M	-$1.36M
Diluted EPS	-28.55	-16.78	-19.20	—	-6.66	-0.98
Diluted Shares	58078	62424	145989	—	341377	1.39M

ISPC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$782.56K	$588.77K	$2.78M	$6.88M	$2.82M	$4.41M
Receivables	$581.65K	$372.47K	$120.93K	$48.30K	$132.85K	$21.26K
Inventory	—	—	—	$0.00	—	—
Current Assets	$1.53M	$1.17M	$3.60M	$6.95M	$3.48M	$4.48M
Total Assets	$6.84M	$6.03M	$9.00M	$9.53M	$6.61M	$7.39M
Current Liabilities	$4.92M	$5.17M	$5.70M	$6.23M	$5.60M	$5.48M
Total Debt	$300.15K	$287.88K	$281.44K	$268.80K	$254.99K	$240.90K
Total Liabilities	$5.17M	$5.41M	$5.92M	$6.44M	$5.80M	$5.66M
Retained Earnings	-$73.52M	-$74.57M	-$77.35M	-$82.35M	-$84.63M	-$85.99M
Shareholders' Equity	$1.67M	$621.97K	$3.07M	$3.09M	$814.04K	$1.74M
Working Capital	-$3.39M	-$4.01M	-$2.10M	$723.28K	-$2.12M	-$992.54K

ISPC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.10M	-$192.23K	-$2.04M	-$916.92K	-$3.36M	-$689.63K
Capital Expenditure	—	—	-$1.00M	—	-$700.00K	—
Free Cash Flow	-$1.10M	-$192.69K	-$3.04M	-$916.92K	-$4.06M	-$689.63K
Depreciation & Amortisation	$432.71K	$432.73K	$457.73K	$407.73K	$135.94K	$201.47K
Stock-Based Compensation	$15.90K	$1.80K	$1.80K	$1.76K	$1.03K	$153.00
Investing Cash Flow	$0.00	-$454.00	-$1.00M	$0.00	-$700.00K	$0.00
Financing Cash Flow	$0.00	-$1.10K	$5.23M	$5.01M	—	—
Share Repurchases	$0.00	$0.00	$0.00	—	—	—
Net Change in Cash	-$1.10M	-$193.79K	$2.19M	$4.10M	-$4.06M	$1.60M

Market Snapshot

About

iSpecimen Inc. operates an online marketplace that connects life science researchers with healthcare specimen providers. The company's technology platform facilitates the procurement of human biospecimens, including blood, tissue, and other biological samples, for use in medical research and drug development. iSpecimen's network includes hospitals, laboratories, and biobanks that supply specimens to pharmaceutical companies, diagnostic companies, and academic researchers. The platform streamlines the traditionally complex and time-consuming process of sourcing biospecimens for research. iSpecimen aims to accelerate medical research and drug discovery by improving access to high-quality human biospecimens.